Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Conference Call April 1, 2025 8:30 AM ET
Company Participants
Christian Kanstrup – Chief Executive Officer
Birgitte Rønø – Chief Scientific Officer
Thomas Schmidt – Chief Financial Officer
Conference Call Participants
Thomas Flaten – Lake Street Capital Markets
Swayampakula Ramakanth – HCW
Operator
Good day, and thank you for standing by. Welcome to the Evaxion Biotech Business Update Full Year 2024 Conference Call and Webcast. At this time, all participants will be in listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please note that today’s conference is being recorded.
I would now like to hand the conference over to your speaker, Christian Kanstrup, CEO. Please go ahead.
Christian Kanstrup
Thank you so much, and good morning and good afternoon to all of you, and a very warm welcome to this Evaxion full year 2024 business update call.
I’m Christian Kanstrup, CEO of Evaxion. With me today, I have Birgitte Rønø, our Chief Science Officer; Thomas Schmidt, our Chief Financial Officer; and Mads Kronborg, our VP of Investor Relations and Communications.
I think it’s fair to say that 2024 was a super exciting year for Evaxion with lots of achievements throughout the year, and we are looking very much forward to be giving you an update on the year.
And the agenda and what we intend to cover. First of all, I will start out recapping on 2024, looking ahead into 2025 and some of the significant milestones that we see in front of us. Birgitte will be taking us through the R&D update. Thomas will cover the 2024 financial results. And I will be having a few conclusive remarks before we, as usual, jump into the Q&A.
And another thing that is as usual is the forward-looking
